KMR Group
Companies that seek to set realistic recruitment expectations should consider using key enrollment benchmarks which combine both disease and geographic information. This permits a more accurate view of enrollment performance based on the differences across regions within a given disease.
For example, in Diabetes the median number of subjects a site randomizes varies by region from four in North America to eight in parts of Asia and Latin America. This makes a significant difference when predicting for the volume of sites that will be needed. To illustrate, the volume of sites needed to achieve 50 subjects in North America would require about 13 sites whereas in Asia or Latin America closer to seven sites would be needed.
The rate of subjects randomized per month by an individual site also varies significantly by region, from 1.2 subjects per month on the low end in North America to 2.8 in Latin America. As a result, it would take over eight months for a site in North America to achieve 10 subjects but in Latin America 10 subjects could be randomized in less than four months.
As demonstrated, setting realistic expectations for investigator sites involves an assessment that takes into account geographic granularity. Only at this level can you foster more accurate planning, not only for the volume of subjects a site can deliver (thus affecting the total sites required) but also for predicting the cycle time for completion of the study.
It is also important to rely on data derived directly from the individual sites in order to determine the number of subjects a given site can obtain or the rate at which a given site can randomize. This is as opposed to simple totals compiled at the trial level, which can generate less reliable results.
At the same time, it is difficult for companies to rely solely on information available internally as the sample sizes are small. Industry benchmarks offer critical advantages: the information is pooled to allow for larger sample sizes and the industry data often provides perspective on what type of performance is most realistic.
KMR Group, http://kmrgroup.com/.
Image Source: KMR Group Enrollment Metrix Application, SiteMetrix
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.